RM-0256 / Rakuten Medical - LARVOL DELTA

Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding (PRNewswire) - "Rakuten Medical...announced that its third drug candidate, RM-0256, has been selected for funding by the Japan Agency for Medical Research and Development (AMED) under its Support Program for Orphan Drug prior to the Designation....RM-0256 targets Programmed Cell Death Ligand 1 (PD-L1), a key immune checkpoint protein that allows tumors to evade immune detection by binding to PD-1 receptors on activated T cells. PD-L1 is widely expressed in various solid tumors-including melanoma, ocular melanoma, lung, urothelial, gastrointestinal, gynecological, breast, and head and neck cancers-as well as on immunosuppressive cells within the tumor microenvironment."

Financing • Breast Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Ocular Melanoma • Urothelial Cancer

Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024 (PRNewswire) - "Rakuten Medical...announces that the research results of the preclinical studies for PD-L1-targeted photoimmunotherapy were presented at the 83rd Annual Meeting of the Japanese Cancer Association (JCA2024)....Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion of PD-L1 expressing immunosuppressive cells. In vivo studies of the treatment resulted in more effective tumor growth suppression compared to anti-PD-L1 antibody alone in an anti-PD-L1 sensitive mouse tumor model and tumor growth suppression compared to saline in an anti-PD-L1 resistant mouse tumor model."

Preclinical • Solid Tumor

Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox Platform (PRNewswire) - "Rakuten Medical...announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital and the conversion of $74 million of convertible promissory notes with accrued interest. Rakuten Medical intends to further develop its proprietary Alluminox platform and contribute to the future of patients and healthcare around the world by allocating the funds raised for the following business priorities: Continuing efforts to accelerate its global Phase 3 clinical trial...; Supporting ongoing clinical trials and initiating new studies for Alluminox treatment using its three key assets (ASP-1929, RM-1995, and RM-0256), including combination therapy with anti-PD-1, which has shown promising early data that Rakuten Medical believes warrant additional clinical studies..."

Financing • Head and Neck Cancer